Actelion hiring investment banker after takeover report; Cell Biosciences buys Convergent for $12M;

 @FierceBiotech: Advisory panel rejections carry the greatest clout at the FDA. Report | Follow @FierceBiotech

 @JohnCFierce: SIGA Tech lands, or almost lands, $2.8B antiviral contract from HHS, shares skyrocket 46 percent. News | Follow @JohnCFierce

> Sources tell Reuters that Switzerland's Actelion is about to hire an investment banker after a European newspaper reported that it is a likely takeover target. The company (ATLN) has a market value of $6 billion. Story

> Cell Biosciences has struck a deal to acquire Convergent Bioscience for about $12 million in cash. Cell release

> Becton Dickinson has landed commercialization rights on iPS technology developed by Fate Therapeutics, which is receiving an unspecified upfront and milestones in the deal. Article

> Talecris says that the FDA approved Gamunex-C for subcutaneous administration in the treatment of primary immunodeficiency. Release

> A stem cell research paper published in Nature is being retracted after doubts were raised about its reliability. Lead author Shane Mayack did not sign the retraction, saying the results of the study are valid. Report

And Finally... Kevin Eggan, the CSO at the New York Stem Cell Foundation, has been taking some good-natured ribbing after being named "Sexy Genius." Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.